DEFA14A ·Filed Apr 27, 2026

QURE

uniQure N.V.
NEUTRAL
Impact 3/10
Horizonimmediate Processed5mo ago SEC0001104659-26-048975
Proxy solicitation materials
Actionable Insight • Neutral

Monitor for any shareholder opposition to the proposals, particularly the share incentive plan amendment and executive compensation, though the board's unanimous endorsement suggests high approval likelihood.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
QURE ▲ +125.59% at T+60d
NEUTRAL call ✓ call won +125.59% · α vs SPY +120.81% · entry $17.90 → $40.38
Entry anchored
Apr 24, 03:59 PM ET
via exchange tick
T+1d
+0.84%
call +0.84% · α +1.32%
$18.05
settled 5mo ago
T+5d
+15.53%
call +15.53% · α +15.13%
$20.68
settled 5mo ago
T+20d
+40.50%
call +40.50% · α +35.55%
$25.15
settled 4mo ago
T+60d
+125.59%
call +125.59% · α +120.81%
$40.38
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

uniQure N.V. (QURE) has filed its definitive proxy statement for the 2026 Annual General Meeting, scheduled for June 10, 2026. The board recommends approval of all 15 proposals, including the reappointment of three non-executive directors, auditor appointment, executive compensation, and a share incentive plan amendment.

Key Facts

  • Annual General Meeting scheduled for June 10, 2026
  • Board recommends approval of all 15 proposals
  • Proposals include reappointment of three non-executive directors (Madhavan Balachandran, Jack Kaye, Leonard Post)
  • Proposal to reauthorize board to repurchase shares
  • Proposal to amend Articles of Association to increase authorized share capital
  • Proposal to approve advisory vote on frequency of executive compensation votes

Financial Impact

No immediate financial impact from routine proxy proposals

governanceexecutive compensationshare count

Risk Factors

  • Potential shareholder dissent on executive compensation (Proposal 10)
  • Possible opposition to increasing authorized share capital (Proposal 14)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (21 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001104659-26-048975
Document: 0001104659-26-048975-index-headers.html0001104659-26-048975
Document: 0001104659-26-048975-index.html0001104659-26-048975
Document: 0001104659-26-048975.txt0001104659-26-048975
32 reports for QURE
Performance horizon
67% Hit rate 6 of 9 directional calls best @ T+20▲ +27.15%Jul 29, 2026
Filters
Rows
Reports for QURE — sortable, filterable
TypeNow
Sep 2, 2026
4w ago
8-K
BULLISH ★ 7/10
$46.23 $44.47▼ −3.81%▼ −2.85%$23.46 (−49.25%)
Jul 29, 2026
9w ago
8-K
BULLISH ★ 8/10
$40.07 $44.24▲ +10.41%▲ +4.88%$23.46 (−41.45%)
Jul 7, 2026
12w ago
Insider Cluster
BEARISH ★ 5/10
$41.41 $41.52▼ −0.27%▲ +0.29%$23.46 (+43.35%)
Jul 2, 2026
13w ago
Insider Cluster
BEARISH ★ 4/10
$41.81 $44.48▼ −6.39%▼ −5.46%$23.46 (+43.89%)
Jul 2, 2026
13w ago
Insider Cluster
MIXED ★ 5/10
$41.81 $44.48▲ +6.39%▲ +5.46%$23.46 (−43.89%)
Jul 2, 2026
13w ago
144
NEUTRAL ★ 2/10
$41.81 $44.48▲ +6.39%▲ +5.46%$23.46 (−43.89%)
Jun 30, 2026
13w ago
144
NEUTRAL ★ 2/10
$45.17 $41.41▼ −8.32%▼ −8.59%$23.46 (−48.06%)
Jun 25, 2026
14w ago
144
BEARISH ★ 5/10
$47.51 $41.81▲ +12.00%▲ +14.16%$23.46 (+50.62%)
Jun 24, 2026
14w ago
424B5
MIXED ★ 6/10
$49.10 $45.17▼ −8.00%▼ −9.56%$23.46 (−52.22%)
Jun 24, 2026
14w ago
144
NEUTRAL ★ 2/10
$49.10 $45.17▼ −8.00%▼ −9.56%$23.46 (−52.22%)
Showing 10 of 32

US Market Status

Market Closed — Opens Mon (64h 21m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access